Imperial College London

DrRichardNicholas

Faculty of MedicineDepartment of Brain Sciences

Professor of Practice (Neurology)
 
 
 
//

Contact

 

r.nicholas

 
 
//

Location

 

12L12CLab BlockCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Chan:2017:10.1016/S1474-4422(17)30113-8,
author = {Chan, D and Binks, S and Nicholas, JM and Frost, C and Cardoso, MJ and Ourselin, S and Wilkie, D and Nicholas, R and Chataway, J},
doi = {10.1016/S1474-4422(17)30113-8},
journal = {Lancet Neurology},
pages = {591--600},
title = {Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial},
url = {http://dx.doi.org/10.1016/S1474-4422(17)30113-8},
volume = {16},
year = {2017}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BackgroundIn the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy, in which we investigated the treatment effect on cognitive, neuropsychiatric, and health-related quality-of-life (HRQoL) outcome measures.MethodsWe did a secondary analysis of MS-STAT, a 24-month, double-blind, controlled trial of patients with SPMS done at three neuroscience centres in the UK between Jan 28, 2008, and Nov 4, 2011. Patients were randomly assigned (1:1) to either 80 mg simvastatin (n=70) or placebo (n=70). The cognitive assessments done were the National Adult Reading Test, Wechsler Abbreviated Scale of Intelligence, Graded Naming Test, Birt Memory and Information Processing Battery (BMIPB), Visual Object and Space Perception battery (cube analysis), Frontal Assessment Battery (FAB), and Paced Auditory Serial Addition Test. Neuropsychiatric status was assessed using the Hamilton Depression Rating Scale and the Neuropsychiatric Inventory Questionnaire. HRQoL was assessed using the self-reported 36-Item Short Form Survey (SF-36) version 2. Assessments were done at study entry, 12 months, and 24 months. Patients, treating physicians, and outcome assessors were masked to treatment allocation. Analyses were by intention to treat. MS-STAT is registered with ClinicalTrials.gov, number NCT00647348.FindingsBaseline assessment revealed impairments in 60 (45%) of 133 patients on the test of frontal lobe function (FAB), and in between 13 (10%) and 43 (33%) of 130 patients in tests of non-verbal and verbal memory (BMIPB). Over the entire trial, we noted significant worsening on tests of verbal memory (T score decline of 5·7 points, 95% CI 3·6–7·8; p<0·0001) and non-verbal memory (decline of 6·8 points, 4·8–8·7; p<0·
AU - Chan,D
AU - Binks,S
AU - Nicholas,JM
AU - Frost,C
AU - Cardoso,MJ
AU - Ourselin,S
AU - Wilkie,D
AU - Nicholas,R
AU - Chataway,J
DO - 10.1016/S1474-4422(17)30113-8
EP - 600
PY - 2017///
SN - 1474-4422
SP - 591
TI - Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial
T2 - Lancet Neurology
UR - http://dx.doi.org/10.1016/S1474-4422(17)30113-8
UR - http://hdl.handle.net/10044/1/52044
VL - 16
ER -